MBP8298

Parent company: BioMS.

Administered intravenously every six months. Proposes to make the immune system tolerant to Myelin Basic.

Protein (target of MS attack), by giving large doses of this synthetic peptide (protein) drug.

Phase II trials showed that versus placebo, MBP8298 safely delayed median time to disease progression by five years in progressive (SPMS) patients.

MAESTRO-01 is an ongoing study with 611 SPMS patients in Canada and Europe; one-year interim safety analysis recommended to continue study as planned.

MINDSET-01 is a phase II trial with RRMS patients in Europe; now fully enrolled with 215 patients.

MAESTRO-03 is a phase III trial (with SPMS patients) in the United States, which began enrolling its 510 patients in June 2007.

Appears to be more effective in patients with certain genetic types, which includes approximately 75 percent of the MS populations.